Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

• Steven Coutre,
• Alessandra Tedeschi,
• Tadeusz Robak,
• Paul M. Barr,
• Carolyn Owen,
• Osnat Bairey,
• Jan Burger,
• Cathy Zhou,
• Lori Styles,
• Danelle F. James,
• Thomas J. Kipps

Affiliations

Steven Coutre

Stanford University School of Medicine, CA, USA

Alessandra Tedeschi

ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Tadeusz Robak

Medical University of Lodz, Poland

Paul M. Barr

Wilmot Cancer Institute, University of Rochester Cancer Center, NY, USA

Carolyn Owen

Tom Baker Cancer Centre, University of Calgary, Canada

Osnat Bairey

Rabin Medical Center, Beilinson Campus, Petah Tikvah, Israel;Sackler Faculty of Medicine, University, Tel Aviv, Israel

Jan Burger

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Cathy Zhou

Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA

Lori Styles

Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA

Danelle F. James

Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA

Thomas J. Kipps

University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA